DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France.
DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France.
复制标题
DOI：
10.1002/acn3.51408
复制
发表时间：
2021-08
影响因子：
5.3
通讯作者：
Covisep study groups
中科院分区：
文献类型：
--
作者：
Sormani MP;Salvetti M;Labauge P;Schiavetti I;Zephir H;Carmisciano L;Bensa C;De Rossi N;Pelletier J;Cordioli C;Vukusic S;Moiola L;Kerschen P;Radaelli M;Théaudin M;Immovilli P;Casez O;Capobianco M;Ciron J;Trojano M;Stankoff B;Créange A;Tedeschi G;Clavelou P;Comi G;Thouvenot E;Battaglia MA;Moreau T;Patti F;De Sèze J;Louapre C;Musc-19;Covisep study groups
我们对来自意大利和法国的两个大型队列进行了汇总分析，评估了DMT对MS患者Covid-19严重程度的影响。通过多变量有序logistic模型评估基线特征和DMT与Covid-19严重程度的相关性，并通过固定效应Meta分析进行汇总。纳入了来自意大利的1066例MS患者和来自法国的721例患者。在多变量模型中，抗CD 20治疗与Covid-19严重程度显著相关（OR = 2.05，95%CI = 1.39-3.02，p < 0.001），而干扰素则表明风险降低（OR = 0.42，95%CI = 0.18-0.99，p = 0.047）。这项汇总分析证实了接受抗CD 20治疗的患者发生严重Covid-19的风险增加，并支持干扰素的保护作用。
We evaluated the effect of DMTs on Covid‐19 severity in patients with MS, with a pooled‐analysis of two large cohorts from Italy and France. The association of baseline characteristics and DMTs with Covid‐19 severity was assessed by multivariate ordinal‐logistic models and pooled by a fixed‐effect meta‐analysis. 1066 patients with MS from Italy and 721 from France were included. In the multivariate model, anti‐CD20 therapies were significantly associated (OR = 2.05, 95%CI = 1.39–3.02, p < 0.001) with Covid‐19 severity, whereas interferon indicated a decreased risk (OR = 0.42, 95%CI = 0.18–0.99, p = 0.047). This pooled‐analysis confirms an increased risk of severe Covid‐19 in patients on anti‐CD20 therapies and supports the protective role of interferon.
登录
查看更多内容
DOI：
10.1056/nejmoa2022926
发表时间：
2020-11-19
期刊：
The New England journal of medicine
影响因子：
--
作者：
RECOVERY Collaborative Group;Horby P;Mafham M;Linsell L;Bell JL;Staplin N;Emberson JR;Wiselka M;Ustianowski A;Elmahi E;Prudon B;Whitehouse T;Felton T;Williams J;Faccenda J;Underwood J;Baillie JK;Chappell LC;Faust SN;Jaki T;Jeffery K;Lim WS;Montgomery A;Rowan K;Tarning J;Watson JA;White NJ;Juszczak E;Haynes R;Landray MJ
通讯作者：
Landray MJ
影响因子：
64.5
作者：
Sette A;Crotty S
通讯作者：
Crotty S
危及生命的Covid-19患者中针对I型IFN的自身抗体。
DOI：
10.1126/science.abd4585
发表时间：
2020-10-23
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Bastard P;Rosen LB;Zhang Q;Michailidis E;Hoffmann HH;Zhang Y;Dorgham K;Philippot Q;Rosain J;Béziat V;Manry J;Shaw E;Haljasmägi L;Peterson P;Lorenzo L;Bizien L;Trouillet-Assant S;Dobbs K;de Jesus AA;Belot A;Kallaste A;Catherinot E;Tandjaoui-Lambiotte Y;Le Pen J;Kerner G;Bigio B;Seeleuthner Y;Yang R;Bolze A;Spaan AN;Delmonte OM;Abers MS;Aiuti A;Casari G;Lampasona V;Piemonti L;Ciceri F;Bilguvar K;Lifton RP;Vasse M;Smadja DM;Migaud M;Hadjadj J;Terrier B;Duffy D;Quintana-Murci L;van de Beek D;Roussel L;Vinh DC;Tangye SG;Haerynck F;Dalmau D;Martinez-Picado J;Brodin P;Nussenzweig MC;Boisson-Dupuis S;Rodríguez-Gallego C;Vogt G;Mogensen TH;Oler AJ;Gu J;Burbelo PD;Cohen JI;Biondi A;Bettini LR;D'Angio M;Bonfanti P;Rossignol P;Mayaux J;Rieux-Laucat F;Husebye ES;Fusco F;Ursini MV;Imberti L;Sottini A;Paghera S;Quiros-Roldan E;Rossi C;Castagnoli R;Montagna D;Licari A;Marseglia GL;Duval X;Ghosn J;HGID Lab;NIAID-USUHS Immune Response to COVID Group;COVID Clinicians;COVID-STORM Clinicians;Imagine COVID Group;French COVID Cohort Study Group;Milieu Intérieur Consortium;CoV-Contact Cohort;Amsterdam UMC Covid-19 Biobank;COVID Human Genetic Effort;Tsang JS;Goldbach-Mansky R;Kisand K;Lionakis MS;Puel A;Zhang SY;Holland SM;Gorochov G;Jouanguy E;Rice CM;Cobat A;Notarangelo LD;Abel L;Su HC;Casanova JL
通讯作者：
Casanova JL
影响因子：
5.1
作者：
Zabalza, Ana;Cardenas-Robledo, Simon;Montalban, Xavier
通讯作者：
Montalban, Xavier
影响因子：
4
作者：
Novi, Giovanni;Bovis, Francesca;Gobbi, Claudio
通讯作者：
Gobbi, Claudio